Tao Wang
Hong Kong Polytechnic University(HK)The Kids Research Institute Australia(AU)The University of Western Australia(AU)Jilin University(CN)Medical College of Wisconsin(US)Renji Hospital(CN)Sir Run Run Shaw Hospital(CN)Chinese PLA General Hospital(CN)Zhengzhou University(CN)Roche (Canada)(CA)Linyi People's Hospital(CN)Versiti Blood Center of Wisconsin(US)Duke Medical Center(US)Henan Cancer Hospital(CN)Union Hospital(CN)Zhejiang University(CN)
Publications by Year
Research Areas
Cancer Cells and Metastasis, Lung Cancer Treatments and Mutations, Extracellular vesicles in disease, Immunotherapy and Immune Responses, Advanced biosensing and bioanalysis techniques
Most-Cited Works
- → Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial(2017)1,186 cited
- → Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics(2020)969 cited
- → Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer(2014)696 cited
- → Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development(2018)501 cited
- → Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations(2018)430 cited
- → Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity